Kasumba, Irene N; Powell, Helen; Omore, Richard; Hossain, M Jahangir; Sow, Samba O; Ochieng, John Benjamin; Badji, Henry; Verani, Jennifer R; Widdowson, Marc-Alain; Sen, Sunil; +21 more... Nasrin, Shamima; Permala-Booth, Jasnehta; Jones, Jennifer A; Roose, Anna; Nasrin, Dilruba; Sugerman, Ciara E; Juma, Jane; Awuor, Alex; Jones, Joquina Chiquita M; Doh, Sanogo; Okoi, Catherine; Zaman, Syed MA; Antonio, Martin; Hunsperger, Elizabeth; Onyango, Clayton; Platts-Mills, James; Liu, Jie; Houpt, Eric; Neuzil, Kathleen M; Kotloff, Karen L; Tennant, Sharon M; (2023) Prevalence of Salmonella in Stool During the Vaccine Impact on Diarrhea in Africa (VIDA) Study, 2015-2018. Clinical Infectious Diseases, 76 (76 Sup). S87-S96. ISSN 1058-4838 DOI: https://doi.org/10.1093/cid/ciac985
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Abstract
BACKGROUND: Non-typhoidal Salmonella (NTS) is a common cause of gastroenteritis in young children, with limited data on NTS serovars and antimicrobial resistance in Africa. METHODS: We determined the prevalence of Salmonella spp. and frequency of antimicrobial resistance among serovars identified in stools of 0-59 month-old children with moderate-to-severe diarrhea (MSD) and controls enrolled in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in The Gambia, Mali, and Kenya in 2015-2018, and compared with data from the Global Enteric Multicenter Study (GEMS; 2007-2010) and the GEMS-1A study (2011). Salmonella spp. was detected by quantitative real-time PCR (qPCR) and culture-based methods. Identification of serovars was determined by microbiological methods. RESULTS: By qPCR, the prevalence of Salmonella spp. among MSD cases was 4.0%, 1.6%, and 1.9% and among controls was 4.6%, 2.4%, and 1.6% in The Gambia, Mali, and Kenya, respectively, during VIDA. We observed year-to-year variation in serovar distribution and variation between sites. In Kenya, Salmonella enterica serovar Typhimurium decreased (78.1% to 23.1%; P < .001) among cases and controls from 2007 to 2018, whereas serogroup O:8 increased (8.7% to 38.5%; P = .04). In The Gambia, serogroup O:7 decreased from 2007 to 2018 (36.3% to 0%; P = .001) but S. enterica serovar Enteritidis increased during VIDA (2015 to 2018; 5.9% to 50%; P = .002). Only 4 Salmonella spp. were isolated in Mali during all 3 studies. Multidrug resistance was 33.9% in Kenya and 0.8% in The Gambia across all 3 studies. Ceftriaxone resistance was only observed in Kenya (2.3%); NTS isolates were susceptible to ciprofloxacin at all sites. CONCLUSIONS: Understanding variability in serovar distribution will be important for the future deployment of vaccines against salmonellosis in Africa.
Item Type | Article |
---|---|
Faculty and Department |
MRC Gambia > GM-Gambia Clinical Services/Comms MRC Gambia > GM-Vaccinology Theme |
PubMed ID | 37074429 |
Elements ID | 205045 |
Official URL | http://dx.doi.org/10.1093/cid/ciac985 |
Download
Filename: Kasumba-etal-2023-Prevalence-of-salmonella-in-stool.pdf
Licence: Creative Commons: Attribution 4.0
Download